France wants to control her on the ground the whole chain of production of the paracetamol in the next three years, announced Thursday the ministries of Economy and Health, two days after the president's call Macron to relocate certain medications.
also Read Vaccine Covid : the provocation be useful to Sanofi
"The work is thus engaged with Seqens, Upsa and Sanofi to that, within three years, France will be able to reproduce, package and distribute paracetamol," said a joint statement of the secretary of State at the ministry of the Economy Agnès Pannier-Runacher and the minister of Health Olivier Véran.
Prevent any shortage
" As of Thursday, we will launch an initiative for the relocation of some production-critical ", had announced on Tuesday the president of the Republic at the end of the visit to a factory Sanofi in Marcy-l'etoile, in the Rhone. "No one can conceive that France is a day in the inability to allow everyone to access to care, treatment and drugs" builds on Thursday, Olivier Véran. In February, a report commissioned by the government made several recommendations on potential shortages of essential drugs.
Read also ' Paracetamol : does it prohibit its sale free ?
At the beginning of the containment, there has been a strong consumer demand for Paracetamol, the active ingredient is paracetamol, a painkiller recommended to treat fever and pain, but no break in the supply chain.
A budget of 200 million production in the pharmaceutical industry
The press release also complements the measures announced Tuesday by the president Macron, and in particular the establishment of an envelope of 200 million euros by 2020 to finance production facilities in the pharmaceutical industry. "The government has already selected six projects for a total amount of 78 million euros," he says before detailing the names of laboratories retained : Abivax, Innate Pharma, Inotrem, Osivax, Xenothera and Genoscience.
also Read : Health warning on acetaminophen
For the other 120 million euros, a call for expressions of interest was published on Thursday in order " to identify investment projects that will grow very quickly the production of drugs involved in the management of patients with Covid-19 ", explain the two departments.
Finally, eight French projects have been selected in the framework of the call for project of EIC (European Innovation Council), launched in march 2020 and will be awarded the amount of 57.4 million euros to fund their research. Four of them (Cypheme, Archeon, Osivax and Xenothera) are directly related to the research on the Covid-19, while the other four (Pkvitality, Exeliom Biosciences, Carthera and Cristalens Industry) are more general.Updated Date: 18 June 2020, 08:33